Top Medical News
5 hours ago
Multidrug resistant bacterial infection is a big threat to human health in low- and middle-income countries (LMICs), leading to a higher risk of mortality, reports a new India study.
Pearl Toh, 7 hours ago
New-generation drug-eluting stents (DES) are superior to early-generation stents in reducing cardiovascular (CV) events and mortality out to 10 years, but there are no significant differences between new-generation stents based on biodegradable polymer and those with permanent polymer, according to the ISAR-TEST* 4 study presented at AHA 2018.
Roshini Claire Anthony, 9 hours ago

Individuals hospitalized with pneumonia have an elevated risk of developing major adverse cardiovascular events (MACE), with a greater risk among those with bacterial compared with viral pneumonia, according to a recent study presented at AHA 2018.

9 hours ago
Adults with bipolar disorder who had been maltreated as a child are more likely to have a medical illness than adults with unipolar depression who have had the same experience, according to a study.
10 hours ago
A new study has exhibited the antitumour activity and manageable safety profile of derazantinib (ARQ 087) in patients with advanced, unresectable intrahepatic cholangiocarcinomas (iCCA) with fibroblast growth factor receptor 2 (FGFR2) who progressed after chemotherapy, according to a new study.
Stephen Padilla, 11 hours ago
Use of triple therapy consisting of a long acting muscarinic antagonist (LAMA), long acting β agonist (LABA) and inhaled corticosteroid (ICS) leads to a reduced rate of moderate or severe exacerbations of chronic obstructive pulmonary disease (COPD) and better lung function and health-related quality of life compared with dual therapy (ICS and LABA or LAMA and LABA) or LAMA monotherapy, according to the results of a meta-analysis.
Stephen Padilla, 11 hours ago
Food insecurity (FI) is associated with risk of hypertension in a large, nationally representative cohort of children and adolescents in the US, independent of obesity, according to a study presented at the American Heart Association (AHA) Scientific Sessions 2018.
Special Reports
21 Nov 2018
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
21 Nov 2018
In conjunction with the launch of Dymista® in Malaysia, Mylan convened a symposium which saw distinguished speakers addressing the allergic rhinitis (AR) landscape in the country and the latest developments in treatment options.
21 Nov 2018
Recently, a Roche-sponsored dinner symposium was held in conjunction with the launch of atezolizumab (Tecentriq®, Roche) at Royale Chulan, Kuala Lumpur. Important insights into the evolving treatment landscape of anticancer treatment, and the increasingly prominent role of immunotherapy were gathered from a distinguished panel, including Dato’ Dr Mohamed Ibrahim, Professor Dr Rolf A. Stahel, Dr Voon Pei Jye, and Associate Professor Dr Tho Lye Mun. Here are the highlights of the meeting.
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

02 Oct 2018
Type 2 diabetes mellitus (T2DM) is associated with substantial risks of cardiovascular disease (CVD) risk and overall mortality, despite the advances in treatment options.1 Recently, MIMS Doctor spoke to Dato’ Sri Dr Azhari Rosman, a Senior Consultant Cardiologist at the National Heart Institute, to provide an update on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in managing CV risk associated with T2DM, and discuss the results of the recently published Comparative Effectiveness of Cardiovascular Outcomes (CVD-REAL) 2 study. Here are the highlights from the interview.
27 Sep 2018
PRALUENT – alirocumab 75 mg/mL and 150 mg/mL soln for inj - sanofi-aventis
Conference Reports
Pearl Toh, 21 Nov 2018
New-generation drug-eluting stents (DES) are superior to early-generation stents in reducing cardiovascular (CV) events and mortality out to 10 years, but there are no significant differences between new-generation stents based on biodegradable polymer and those with permanent polymer, according to the ISAR-TEST* 4 study presented at AHA 2018.
Roshini Claire Anthony, 21 Nov 2018

Individuals hospitalized with pneumonia have an elevated risk of developing major adverse cardiovascular events (MACE), with a greater risk among those with bacterial compared with viral pneumonia, according to a recent study presented at AHA 2018.

Stephen Padilla, 21 Nov 2018
Food insecurity (FI) is associated with risk of hypertension in a large, nationally representative cohort of children and adolescents in the US, independent of obesity, according to a study presented at the American Heart Association (AHA) Scientific Sessions 2018.
Stephen Padilla, 21 Nov 2018
Higher ideal levels of dietary intake, physical activity, smoking, blood pressure (BP), cholesterol and body mass index (BMI) are associated with a dose-dependent lower risk of type 2 diabetes (T2D) for individuals with normal fasting glucose but not impaired fasting glucose, according to a study presented at the American Heart Association (AHA) Scientific Sessions 2018.
Jairia Dela Cruz, 21 Nov 2018
An increased abundance of eicosapentaenoic acid is associated with a reduced risk of heart failure, and this protective effect is independent of established risk factors and ejection fraction status, according to a study presented at the 2018 American Heart Association (AHA) Scientific Sessions in Chicago, Illinois, US.
Audrey Abella, 21 Nov 2018
The use of low-dose intracoronary alteplase, a tissue plasminogen activator (tPA), in patients with acute ST-elevation myocardial infarction (STEMI) at the time of primary percutaneous coronary intervention (PCI) was ineffective in reducing microvascular obstruction (MVO, or failed myocardial reperfusion), according to the T-TIME* trial results presented at AHA 2018.
Tristan Manalac, 21 Nov 2018
The HemosIL ThromboPath assay is highly sensitive to abnormalities in the protein C (PC) pathway in unselected patients, according to a new study presented at the recent American Heart Association Scientific Session 2018 (AHA 2018), held in Chicago, Illinois.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download